| |
|
|
|
Cytomx Thera  
|
|
7.52 0.1 (0.01%) |
11-30 16:00 |
|
Open: |
7.37 |
Pre close: |
7.42 |
Target:
|
9.17
|
|
High: |
7.65 |
Low: |
7.37 |
Resistance:
|
7.85
9.17
|
|
Volume: |
450,223 |
Market Cap: |
348M |
Support:
|
6.95
6.40
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
7.40
 |
MACD |
MACD(12,26):
|
0.14 |
|
MA(20): |
7.25 |
Signal(12,26,9): |
0.14 |
|
MA(100): |
7.18  |
Stochastic Oscillator |
%K(14,3):
|
60.11 |
|
MA(250): |
7.72 |
%D(3): |
58.89 |
|
Average Volume(K) |
3-Month: |
41037
|
52-Week |
High:
|
15.44 |
|
10-Days: |
33987 |
Low: |
3.60 |
|
RSI |
RSI(14):
|
61.34 |
Change(%): |
18.5 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.170 |
Return on Equity (ttm) |
-82.4 |
Shares Out. (M) |
46.22 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-11.9 |
Shares Float (M) |
35.44 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.66 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
66.1 |
% Held by Institutions |
87.46 |
|
Forward EPS |
-2.260 |
Gross Profit (p.s.) |
1.244 |
Shares Short (K) |
3950 |
|
Book Value (p.s.) |
1.040 |
EBITDA (p.s.) |
-1.486 |
P/E |
-6.43 |
|
Sales Per Share |
1.996 |
Qtrly Earnings Growth |
0.00 |
P/BV |
7.23 |
|
Profit Margin |
-58.13 |
Operating Cash Flow
(M) |
-6.79 |
P/S |
3.77 |
|
Operating Margin |
-77.17 |
Levered Free Cash Flow
(M) |
-13.71 |
P/CF |
-51.19 |
|
|
|
|
|
|
